<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1001233082
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARENA 150MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        45.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Arena&trade; belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Arena&trade; prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower. Arena&trade; slows the decrease of kidney function in patients with high blood pressure and type 2 diabetes.</p><p dir="ltr"><strong>Arena&trade; is used</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat high blood pressure (essential hypertension).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to protect the kidney in patients with high blood pressure, type 2 diabetic patients with laboratory evidence of impaired renal function.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Arena&trade;</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to irbesartan or any other ingredients of Arena&trade;.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months <strong>pregnant. </strong>(It is also better to avoid Arena&trade; in early pregnancy-see pregnancy section).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arena&trade; should not be given to <strong>children and adolescents </strong>(under 18 years).</p><p dir="ltr"><strong>Take special care with Arena&trade;</strong></p><p dir="ltr">Tell your doctor if any of the following apply to you:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from excessive <strong>vomiting </strong>or <strong>diarrhoea.</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from <strong>kidney problems.</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from <strong>heart problems.</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you receive Arena&trade; for <strong>diabetic kidney disease. </strong>In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are going to have an <strong>operation </strong>(surgery) or be given <strong>anaesthetics.</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p dir="ltr">Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p dir="ltr">See also information under the heading &ldquo;Do not take Arena&trade;&rdquo;.</p><p dir="ltr">You must tell your doctor if you think that you are (or might become) pregnant. Irbesartan is not recommended in early pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p dir="ltr"><strong>Taking other medicines</strong></p><p dir="ltr">Please <strong>tell your doctor or pharmacist </strong>if you are taking or have recently taken any other</p><p dir="ltr">medicines, including medicines obtained without a prescription.</p><p dir="ltr">If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Arena&trade;&rdquo; and &ldquo;Take special care with Arena&trade;&rdquo;).</p><p dir="ltr"><strong>You may need to have blood checks if you take:</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium supplements.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; salt substitutes containing potassium.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium-sparing medicines (such as certain diuretics).</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing lithium.</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take certain painkillers, called non-steroidal anti- inflammatory drugs, the effect of Arena&trade; may be reduced.</p><p dir="ltr"><strong>Taking Arena&trade; tablets with food and drink</strong></p><p dir="ltr">Arena&trade; can be taken with or without food. The tablets should be swallowed with a drink of water.</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr">Ask your doctor or pharmacist for advice before taking any medicine.</p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr">You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Arena&trade; before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Arena&trade;. Arena&trade; is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p dir="ltr"><strong>Breast feeding</strong></p><p dir="ltr">Tell your doctor if you are breast-feeding or about to start breast-feeding. Arena&trade; are not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast. feed, especially if your baby is newborn, or was born prematurely.</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">No studies on the effects on the ability to drive and use machines have been performed. Arena&trade; are unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting such activities.</p><p dir="ltr"><strong>Important information about the ingredients of Arena&trade;</strong></p><p dir="ltr">These tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take Arena&trade; exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p dir="ltr"><strong>Method of administration</strong></p><p dir="ltr">Arena&trade; are for oral use and are taken with or without food. The tablets should be swallowed with a drink of water. You should try to take your daily dose at about the same time each day. It is important that you continue to take Arena&trade; until your doctor tells you otherwise.</p><p dir="ltr"><strong>Patients with high blood pressure</strong></p><p dir="ltr">The usual dose is 150 mg once a day. The dose may later be increased to 300 mg once daily depending on blood pressure response.</p><p dir="ltr"><strong>Patients with high blood pressure and type 2 diabetes with kidney disease</strong></p><p dir="ltr">In patients with high blood pressure and type 2 diabetes, 300 mg once daily is the preferred maintenance dose for the treatment of associated kidney disease.</p><p dir="ltr">The doctor may advise a lower dose, especially when starting treatment in certain patients such as those on haemodialysis, or those over the age of 75 years.</p><p dir="ltr">The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.</p><p dir="ltr"><strong>Children should not take Arena&trade;</strong></p><p dir="ltr">Arena&trade; should not be given to children (&lt; 18 years).</p><p dir="ltr"><strong>If you take more Arena&trade; tablets than you should</strong></p><p dir="ltr">If you accidentally take too many tablets, or a child swallows some, contact your doctor immediately. Symptoms of overdose can be hypotension and tachycardia; bradycardia.</p><p dir="ltr"><strong>If you forget to take Arena&trade;</strong></p><p dir="ltr">If you accidentally miss a daily dose, just take the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p dir="ltr">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p dir="ltr">Some of these effects may be serious and may require medical attention.</p><p dir="ltr">As with similar medicines, rare cases of allergic skin reactions (rash, urticaria), as well as localized swelling of the face, lips and/or tongue have been reported in patients taking Arena&trade;. If you get any of these symptoms or get short of breath, stop taking Arena&trade; and contact your doctor immediately.</p><p dir="ltr">The frequency of the side effects listed below is defined using the following convention:</p><p dir="ltr">Very common: affects more than 1 user in 10 people.</p><p dir="ltr">Common: affects 1 to 10 users in 100 people.</p><p dir="ltr">Uncommon: affects I to 10 users in 1,000 people.</p><p dir="ltr">Rare: affects 1 to 10 users in 10,000 people.</p><p dir="ltr">Very rare: affects less than 1 user in 10,000 people.</p><p dir="ltr">Not known: frequency cannot be estimated from the available data.</p><p dir="ltr">Side effects reported in clinical studies for patients treated with irbesartan were:</p><p dir="ltr"><u>Very common:</u> if you suffer from high blood pressure and type 2 diabetes with kidney disease, blood tests may show an increased level of potassium.</p><p dir="ltr"><u>Common:</u> dizziness, feeling sick/vomiting, fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme). In patients with high blood pressure and type 2 diabetes with kidney disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.</p><p dir="ltr"><u>Uncommon:</u> heart rate increased, flushing, cough, diarrhoea, indigestion/heartburn, sexual dysfunction (problems with sexual performance), chest pain.</p><p dir="ltr">Some side-effects have been reported since marketing of irbesartan but the frequency for them to occur is not known. These side-effects are: feeling of spinning, headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, abnormal liver function, increased blood potassium levels, impaired kidney function, and inflammation of small blood vessels mainly affecting the skin (a condition known as leukocytoclastic vasculitis).</p><p dir="ltr">If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach of children.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30 &ordm;C.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Arena&trade; tablets after the expiry date which is stated on the carton and on the blister after EXP.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active substance is irbesartan. Each tablet contains 150 mg or 300 mg of irbesartan.</p><p dir="ltr">The other ingredients are aerosil 200 (colloidal silicon dioxide), croscarmellose sodium, lactose anhydrous, magnesium stearate, maize starch, microcrystalline cellulose, poloxamer and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Arena 150mg Tablets : White to off white, round, biconvex, uncoated tablets, engraved with 'JP 113' on one side and plain on the other side.
Arena 300mg Tablets: White to off white, oblong shaped, biconvex, uncoated tablets, engraved with 'JP 115' on one side and plain on the other side.
Arena™ tablets available in 150 mg & 300 mg tablets in boxes of 30 tablets each.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Jamjoom Pharmaceuticals Co., Jeddah, Saudi Arabia.</p><p dir="ltr">Tel: +966-12-6081111, Fax: +966-12-6081222</p><p dir="ltr">Website: www.jamjoompharma.com</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p dir="ltr"><strong>&bull; Saudi Arabia:</strong></p><p dir="ltr">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p dir="ltr">o Fax: +966-11-205-7662</p><p dir="ltr">o Call NPC at +966-11-2038222, Ext: 2317-2356-2340.</p><p dir="ltr">o Reporting hotline: 19999</p><p dir="ltr">o E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">o Website: www.sfda.gov.sa/npc</p><p dir="ltr">&bull; Other GCC States:</p><p dir="ltr">&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>أرينا<sup>&trade;</sup></strong><strong><sup> </sup></strong>ينتمى إلى مجموعة من الأدوية تسمى &quot;مثبطات مستقبلات الأنچيوتنسين.&quot; II &ndash;</p><p dir="RTL">الأنچيوتنسين II&ndash;هو مادة ينتجها الجسم ترتبط بمستقبلات موجودة فى الأوعية الدموية فتجعلها تنقبض مما ينتج عنه ارتفاع في الأنچيوتنسين II&ndash;بهذه المستقبلات، مما يسبب تمدد هذه الأوعية وانخفاض ضغط الدم.</p><p dir="RTL"><strong>أرينا<sup>&trade;</sup></strong> يبطىء من تدهور وظائف الكلى فى المرضى المصابين بارتفاع ضغط الدم و داء السكري من النوع الثاني معا.</p><p dir="RTL"><strong>يستخدم في أرينا<sup>&trade;</sup></strong></p><p dir="RTL">&bull; علاج ارتفاع ضغط الدم.</p><p dir="RTL">&bull; حماية الكلى لدى المرضى المصابين بارتفاع ضغط الدم وداء السكري من النوع الثاني معاً والذين لديهم خلل فى وظائف الكلى أظهرته الاختبارات المعملية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp; &nbsp;قبل أن تتناول أرينا<sup>&trade;</sup>.</strong></p><p dir="RTL"><strong>&nbsp;لا تتناول أرينا<sup>&trade; </sup>في الحالات الآتية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من حساسية مفرطة لإربيسارتان أو أى من المكونات الأخرى لهذا الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الشهر الثالث من الحمل. من المفضل أيضا أن لا يستخدم <strong>أرينا<sup>&trade;</sup></strong> فى المرحلة الأولى من الحمل (انظر إلى الجزء الخاص بالحمل).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض السكري أو اختلال وظائف الكلى و تعالج بأدوية خافضة لضغط الدم تحتوي على أليسكيرين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجب إعطاء <strong>أرينا<sup>&trade; </sup></strong>للأطفال و المراهقين تحت سن ۱۸ عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>أعط عناية خاصة عند تناول أرينا<sup>&trade;:</sup></strong></p><p dir="RTL">يرجى اخبار الطبيب فى الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من قىء أو إسهال شديد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من مشاكل فى الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من مشاكل فى القلب.</p><p dir="RTL">&nbsp;لو كنت تتناول <strong>أرينا<sup>&trade; </sup></strong>لمرض الكلية السكري. فى هذه الحالة سوف يجري لك الطبيب فحوصات الدم بإنتظام خاصة لقياس مستويات البوتاسيوم فى الدم و في حالة ضعف وظائف الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف تجرى عملية جراحية أو سوف تتناول أدوية مخدرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ أي من الأدوية التالية التى تستخدم لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">- <strong>&nbsp;مثبطات الإنزيم المحول للأنجيوتنسين</strong> (على سبيل المثال إنالابريل، ليزينوبريل، راميبريل)، خاصة إذا كان لديك مشاكل في الكلى-متصلة بالسكري.</p><p dir="RTL">- أليسكيرين.</p><p dir="RTL">طبيبك قد يفحص وظيفة الكلى الخاصة بك، ضغط الدم، وكمية الأملاح (مثل البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL">انظر أيضا المعلومات تحت عنوان &quot;لا تناول أرينا<sup>&trade;&quot;</sup></p><p dir="RTL">يجب اخبار الطبيب إذا كنتِ حاملا أو تشكين فى كونك حاملاً. لا يوصى باستخدام إربيسارتان فى المرحلة الأولى من الحمل ولا يجب أن يؤخذ بعد مرور الشهر الثالث من الحمل لأنه قد يسبب ضرر خطير للجنين إذا ما استخدم فى هذه المرحلة (انظر إلى الجزء الخاص بالحمل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى. هذا يشمل الأدوية التى يمكنك شراؤها بدون وصفة طبية.</p><p dir="RTL">إذا كنت تتناول مثبطات الإنزيم المحول للأنجيوتنسين أو أليسكيرين (انظر أيضا المعلومات تحت عناوين &quot;لا تناول أرينا<sup>&trade;</sup>&quot; و&quot;أعط عناية خاصة عند تناول أرينا<sup>&trade;</sup>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تحتاج لأن تجرى بعض فحوصات الدم إذا كنت تتناول الآتي</strong><strong> :</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدائل الملح المحتوية على البوتاسيوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الحافظة للبوتاسيوم مثل بعض مدرات البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المحتوية على الليثيوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول بعض الأدوية المسكنة التى تسمى &quot;مضادات الإلتهاب غير الإستيرويدية&quot;، ربما يقلل ذلك من مفعول أرينا<sup>&trade;</sup>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مع الطعام و الشراب تناول أقراص أرينا&trade;</strong></p><p dir="RTL">يمكن تناول أقراص <strong>أرينا&trade;</strong>مع أو بدون الطعام . يجب بلع الأقراص مع شربة ماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل و الرضاعة</strong></p><p dir="RTL">استشيرى الطبيب أو الصيدلى قبل تناول أى أدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب اخبار الطبيب إذا كنتِ حاملاً أو تشكين فى كونك حاملاً. سوف ينصحك طبيبك بوقف تناول أرينا&trade; قبل الحمل أو بمجرد معرفتك بالحمل وسوف ينصحك أيضا بتناول دواء آخر بدلاً من أرينا&trade;.</p><p dir="RTL">لا يوصى بإستخدام أرينا&trade; فى المرحلة الأولى من الحمل و لا يجب أن يؤخذ بعد مرور الشهر الثالث من الحمل لأنه قد يسبب ضرر خطير للجنين إذا ما استخدم بعد الشهر الثالث من الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الرضاعة</strong></p><p dir="RTL">يرجى اخبار طبيبك إذا كنتِ ترضعين طبيعياً أوعلى وشك البدء فى الرضاعة الطبيعية.</p><p dir="RTL">لا يوصى بإستخدام أرينا&trade; للسيدات المرضعات وقد يختار طبيبك دواء آخر إذا كنتِ تريدين أن ترضعين طفلك طبيعياً خاصة إذا كان طفلك حديث الولادة أو كان غير مكتمل النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات و تشغيل الآلات</strong></p><p dir="RTL">لم يتم إجراء أية دراسات لتوضيح تأثير أرينا&trade;على القدرة على القيادة أواستخدام الآلات.</p><p dir="RTL">من غير المحتمل أن يؤثر أرينا&trade; في قدرتك على القيادة أو استخدام الآلات. بالرغم من ذلك، فى بعض الأحيان قد يحدث دوار وتعب أثناء علاج ارتفاع ضغط الدم. إذا حدث هذا لك، تحدث مع طبيبك قبل القيام بهذه الأنشطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول مكونات أرينا&trade;</strong></p><p dir="RTL">هذه الاقراص تحتوي على اللاكتوز. إذا أخبرك طبيبك أنه لا يمكنك هضم أو تحمل بعض السكريات (مثل اللاكتوز)، أخبر الطبيبك بهذا قبل البدء فى تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تتناول أرينا</strong><strong>&trade;</strong></p><p dir="RTL">قم دائما بتناول أرينا<strong>&trade;</strong><strong> </strong>كما أخبرك طبيبك تماما. يجب عليك مراجعة الطبيب أو الصيدلي إذا كنت غير متأكد من طريقة الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">أقراص أرينا<strong>&trade;</strong><strong> </strong>تؤخذ عن طريق الفم مع أو بدون الطعام. يجب بلع الأقراص مع شربة ماء.</p><p dir="RTL">يجب أن تحاول أن تتناول جرعتك اليومية فى نفس الوقت يوميا.</p><p dir="RTL">من المهم أن تستمر فى تناول أرينا&trade;حتى يطلب منك الطبيب أن تتوقف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص المصابون بارتفاع ضغط الدم</strong></p><p dir="RTL">الجرعة المعتادة هى ۱٥۰ ملجم مرة يوميا.</p><p dir="RTL">قد تزداد الجرعة فيما بعد لتصل إلى ۳۰۰ ملجم يوميا استناداً إلى مدى استجابة ضغط الدم لديك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأشخاص المصابون بارتفاع ضغط الدم وداء السكري من النوع الثاني المصاحب بمرض الكلى</strong></p><p dir="RTL">في الأشخاص المصابون بارتفاع ضغط الدم وداء السكري ( من النوع الثاني) معا، ۳۰۰ ملجم مرة يومياً وهي جرعة المداومة الأنسب لعلاج مرض الكلى المصاحب لهذه الحالة.</p><p dir="RTL">قد ينصحك طبيبك أن تتناول جرعة أقل خاصة عند بدء العلاج فى بعض الأشخاص مثل الذين يجرون غسيل الكلى أو الأشخاص أكبر من 75 عام.</p><p dir="RTL">يجب الوصول إلى أقصى مفعول خافض للدم بعد مرور ٤-٦ أسابيع منذ بدء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا يجب أن يتناول الأطفال أرينا</strong><strong>&trade;</strong></p><p dir="RTL">لا يجب إعطاء أرينا&trade; للأطفال أقل من 18 عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تناولت أرينا</strong><strong>&trade;</strong><strong> أكثر مما ينبغى:</strong></p><p dir="RTL">إذا تناولت عن طريق الخطأ العديد من أقراص أرينا<strong>&trade; </strong>أو قام طفلك ببلع بعضها، اتصل بالطبيب على الفور. &nbsp;</p><p dir="RTL">أعراض الجرعة الزائدة قد تكون انخفاض ضغط الدم ، تسارُّع القلب أو بُطء القلب.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت أن تتناول أرينا</strong><strong>&trade;:</strong></p><p dir="RTL">إذا نسيت أن تتناول جرعتك اليومية ، فقط خذ جرعتك التالية كما هو معتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا كانت لديك أى أسئلة عن استخدام هذا الدواء ، يجب أن تستشير الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية ، هذا الدواء يمكن أن يسبب آثاراً جانبية لكنها لا تصيب كل الأشخاص.</p><p dir="RTL">بعض هذه الآثار قد تكون خطيرة و قد تتطلب عناية طبية.</p><p dir="RTL">كما هو الحال مع الأدوية المماثلة ، فى حالات نادرة قد تم الإبلاغ عن حدوث حساسية الجلد (الطفح الجلدى) وتورم موضعي فى الوجه، الشفتين و / أو اللسان فى المرضى الذين يتناولون أرينا&trade; إذا حدث لك أى من هذه الأعراض أو شعرت بضيق في التنفس ، توقف عن تناول أرينا&trade; واتصل على الفور بطبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدى شيوع الآثار الجانبية المذكورة بالأسفل تم التعبير عنها باستخدام المصطلحات الآتية:</p><p dir="RTL">آثار جانبية شائعة جدا: تصيب أكثر من ۱ من كل ۱۰ أشخاص يستخدمون هذا الدواء.</p><p dir="RTL">آثار جانبية شائعة: تصيب ۱ إلى ۱۰ من كل ۱۰۰ شخص يستخدم هذا الدواء.</p><p dir="RTL">آثار جانبية غير شائعة: تصيب ۱ إلى ۱۰ من كل ۱۰۰۰ شخص يستخدم هذا الدواء.</p><p dir="RTL">آثار جانبية نادرة: تصيب ۱ إلى ۱۰ من كل ۱۰۰۰۰ شخص يستخدم هذا الدواء.</p><p dir="RTL">آثار جانبية نادرة جدا: تصيب أقل من ۱ من كل ۱۰۰۰۰ شخص يستخدمون هذا الدواء.</p><p dir="RTL">مدى الشيوع غير معروف: مدى شيوع هذه الأعراض لا يمكن معرفته من البيانات المتاحة.</p><p dir="RTL">الآثار الجانبية التى تم الإبلاغ عنها فى الدراسات السريرية التى أجريت على المرضى الذين يتناولون إربيسارتان هي :</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة جدا</strong></p><p dir="RTL">إذا كنت تعانى من ارتفاع ضغط الدم و داء السكري من النوع الثاني مع مرض في الكلى، فحوصات الدم قد تظهر ارتفاع مستوى البوتاسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة</strong></p><p dir="RTL">دوار، غثيان، قىء، إرهاق و فحوصات الدم قد تظهر ارتفاع مستوى الإنزيم الذى يستخدم لقياس وظيفة القلب و العضلات ) إنزيم الكرياتينين كيناز).</p><p dir="RTL">فى المرضى الذين يعانون من ارتفاع ضغط الدم و داء السكري من النوع الثاني مع مرض فى الكلى: دوار عند النهوض من وضع الإستلقاء أو عند النهوض من الجلوس ، إنخفاض ضغط الدم عند النهوض من وضع الإستلقاء أو عند النهوض من الجلوس، ألم فى المفاصل أو العضلات و إنخفاض مستوى البروتين فى خلايا الدم الحمراء (الهيموجلوبين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة</strong></p><p dir="RTL">زيادة معدل ضربات القلب، الشعور بهبات ساخنة، سعال، إسهال، عسر هضم/ حموضة المعدة ، ضعف جنسى ، ألم فى الصدر.</p><p dir="RTL">بعض الآثار الجانبية قد تم الإبلاغ عن حدوثها منذ البدء فى تسويق إربيسارتان ولكن مدى شيوع هذه الأعراض غير معروف.</p><p dir="RTL">هذه الأعراض تشمل: شعور بالنخز، صداع، إضطراب فى حاسة التذوق، طنين الأذن، تشنجات العضلات، ألم فى المفاصل والعضلات ، وظائف كبد غير طبيعية ، ارتفاع مستويات البوتاسيوم فى الدم، ضعف فى وظائف الكلى و التهاب الأوعية الدموية الصغيرة تؤثر على الجلد بشكل خاص (حالة تعرف بالتهاب الأوعية الكاسر للكريات البيضاء).</p><p dir="RTL">إذا وصلت أحد الآثار الجانبية لهذا الدواء لمرحلة الخطر أو ظهرت آثار جانبية جديدة لم تذكر في هذه النشرة يرجى إخبارالطبيب أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف تقوم بحفظ أرينا</strong><strong>&trade;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول هذا الدواء بعد انتهاء فترة الصلاحية المكتوبة على العلبة و على الشرائط .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر إلقائها فى بالوعات الصرف أو فى مخلفات المنزل . ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مما يتكون أرينا</strong><strong>&trade;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هى إربيسارتان. كل قرص يحتوى على ۱٥۰ ملجم أو ۳۰۰ ملجم إربيسارتان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى تشمل: إيروسيل ۲۰۰ (ثاني أكسيد السيليكون الغروي)، كروسكرميللوز صوديوم، لاكتوز لامائي، ستيرات المغنيسيوم، نشا الذرة، ميكروكرستلين سليلوز ، بولوكسامير و ماء منقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل أقراص أرينا&trade; وما هو محتوى العلبة </strong></p><p dir="RTL">أقراص أرينا&trade; 150 ملجم : لونها أبيض أو مائل للأبيض، دائرية، محدبة الوجهين، غيرمغلفة، محفورة &#39;113&#39;JP &nbsp;على جانب واحد ومستوية على الجانب الآخر.</p><p dir="RTL">أقراص أرينا&trade; 300 ملجم: لونها أبيض أو مائل للأبيض، بيضاوية الشكل، محدبة الوجهين، غيرمغلفة، محفورة &#39;115&#39;JP &nbsp;على جانب واحد ومستوية على الجانب الآخر.</p><p dir="RTL">أرينا&trade; أقراص متوفرة في عبوات 150 ملجم و 300 ملجم أقراص كل عبوة بها 30 قرص.</p><p dir="RTL">قد لا تكون كل العبوات مطروحة للتسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق و المصنع</strong><strong>:</strong></p><p dir="RTL">شركة مصنع جمجوم للأدوية، جدة، المملكة العربية السعودية.</p><p dir="RTL">+۹٦٦-۱۲- ۹٦٦ + فاكس: ٦۰۸۱۲۲۲ -۱۲- هاتف: ٦۰۸۱۱۱۱</p><p dir="RTL">الموقع الإلكتروني www.jamjoompharma.com :</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي أثار جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL">- المركز الوطني للتيقظ والسلامة الدوائية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: +966-11-205-7662</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: +966-11-2038222</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحويلة: 2317-2356-2340</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط الساخن للإبلاغ: 1999</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريد إلكترونيnpc.drug@sfda.gov.sa :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p dir="RTL"><strong>&bull; </strong><strong>دول الخليج الأخرى</strong><strong>:</strong></p><p dir="RTL">- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2019/06
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arena  150 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 150 mg of Irbesartan.
Excipient with known effect: 50.00 mg of lactose anhydrous per tablet.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
White to off white, 9.5 mm, round, biconvex, uncoated tablets, engraved with 'JP 113' on one side and
plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan is indicated in adults for the treatment of essential hypertension.<br />It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2<br />diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and<br />5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />The usual recommended initial and maintenance dose is 150 mg once daily, with or without food.<br />Irbesartan at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control<br />than 75 mg. However, initiation of therapy with 75 mg could be considered, particularly in<br />haemodialysed patients and in the elderly over 75 years.</p><p>In patients insufficiently controlled with 150 mg once daily, the dose of Irbesartan can be increased to<br />300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In particular,<br />the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with<br />Irbesartan (see section 4.5).<br />In hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg Irbesartan once daily and<br />titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease.<br />The demonstration of renal benefit of Irbesartan in hypertensive type 2 diabetic patients is based on<br />studies where Irbesartan was used in addition to other antihypertensive agents, as needed, to reach<br />target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<br />Special Populations<br />Renal impairment: no dosage adjustment is necessary in patients with impaired renal function. A lower<br />starting dose (75 mg) should be considered for patients undergoing haemodialysis (see section 4.4).<br />Hepatic impairment: no dosage adjustment is necessary in patients with mild to moderate hepatic<br />impairment. There is no clinical experience in patients with severe hepatic impairment.<br />Older people: although consideration should be given to initiating therapy with 75 mg in patients over<br />75 years of age, dosage adjustment is not usually necessary for older people.<br />Paediatric population: the safety and efficacy of Irbesartan in children aged 0 to 18 has not been<br />established. Currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation<br />on a posology can be made.<br />Method of Administration<br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
The concomitant use of Irbesartan with aliskiren-containing products is contraindicated in patients with
diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see
sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in<br />patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction,<br />diarrhoea or vomiting. Such conditions should be corrected before the administration of Irbesartan.<br />Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency<br />when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney<br />are treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is<br />not documented with Irbesartan, a similar effect should be anticipated with angiotensin-II receptor<br />antagonists.<br />Renal impairment and kidney transplantation: when Irbesartan is used in patients with impaired renal<br />function, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no<br />experience regarding the administration of Irbesartan in patients with recent kidney transplantation.<br />Hypertensive patients with type 2diabetesandrenaldisease: the effects of Irbesartan both on renal and<br />cardiovascular events were not uniform across all subgroups, in an analysis carried out in the study<br />with patients with advanced renal disease. In particular, they appeared less favourable in women and<br />non-white subjects (see section 5.1).<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS):<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute<br />renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II&nbsp;receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade<br />therapy is considered absolutely necessary, this should only occur under specialist supervision and<br />subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors<br />and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic<br />nephropathy.<br />Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system,<br />hyperkalaemia may occur during the treatment with Irbesartan, especially in the presence of renal<br />impairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of<br />serum potassium in patients at risk is recommended (see section 4.5).<br />Lithium: the combination of lithium and Irbesartan is not recommended (see section 4.5). Aortic and<br />mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special<br />caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive<br />hypertrophic cardiomyopathy.<br />Primary aldosteronism: patients with primary aldosteronism generally will not respond to<br />antihypertensive medicinal products acting through inhibition of the renin-angiotensin system.<br />Therefore, the use of Irbesartan is not recommended.<br />General: in patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying<br />renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors<br />or angiotensin-II receptor antagonists that affect this system has been associated with acute<br />hypotension, azotaemia, oliguria, or rarely acute renal failure. As with any antihypertensive agent,<br />excessive blood pressure decrease in patients with ischaemic cardiopathy or ischaemic cardiovascular<br />disease could result in a myocardial infarction or stroke.<br />As observed for angiotensin converting enzyme inhibitors, Irbesartan and the other angiotensin<br />antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks,<br />possibly because of higher prevalence of low-renin states in the black hypertensive population (see<br />section 5.1).</p><p>Pregnancy: Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy.<br />Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be<br />changed to alternative antihypertensive treatments which have an established safety profile for use in<br />pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,<br />if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Lactose: this medicinal product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this<br />medicinal product.<br />Paediatric population: Irbesartan has been studied in paediatric populations aged 6 to 16 years old but<br />the current data are insufficient to support an extension of the use in children until further data become<br />available (see sections 4.8, 5.1 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Diuretics and other antihypertensive agents: other antihypertensive agents may increase the hypotensive<br />effects of Irbesartan; however Irbesartan has been safely administered with other antihypertensive<br />agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide diuretics. Prior<br />treatment with high dose diuretics may result in volume depletion and a risk of hypotension when<br />initiating therapy with Irbesartan (see section 4.4).<br />Aliskiren-containingproducts or ACE-inhibitors: Clinical trial data has shown that dual blockade of the<br />renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors,<br />angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events<br />such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure)<br />compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). Potassium<br />supplements and potassium-sparing diuretics: based on experience with the use of other medicinal<br />products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics,<br />potassium supplements, salt substitutes containing potassium or other medicinal products that may<br />increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is,<br />therefore, not recommended (see section 4.4).</p><p>Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects<br />have been very rarely reported with Irbesartan so far. Therefore, this combination is not recommended<br />(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is<br />recommended.<br />Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered<br />simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors,<br />acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect<br />may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an<br />increased risk of worsening of renal function, including possible acute renal failure, and an increase in<br />serum potassium, especially in patients with poor pre-existing renal function. The combination should<br />be administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy, and<br />periodically thereafter.<br />Additional information on Irbesartan interactions: in clinical studies, the pharmacokinetic of Irbesartan<br />is not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser<br />extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were<br />observed when Irbesartan was coadministered with warfarin, a medicinal product metabolised by<br />CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of Irbesartan<br />have not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of<br />Irbesartan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:<br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The<br />use of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections<br />4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors<br />during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot<br />be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II<br />Receptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA<br />therapy is considered essential, patients planning pregnancy should be changed to alternative<br />antihypertensive treatments which have an established safety profile for use in pregnancy. When<br />pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate,<br />alternative therapy should be started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human<br />fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal<br />toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of<br />renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3<br />and 4.4).<br />Breast-feeding:<br />Because no information is available regarding the use of Irbesartan during breast-feeding, Irbesartan is<br />not recommended and alternative treatments with better established safety profiles during breastfeeding<br />are preferable, especially while nursing a newborn or preterm infant.<br />It is unknown whether Irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of Irbesartan or its<br />metabolites in milk (for details see 5.3).</p><p>&nbsp;</p><p>Fertility<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing<br />the first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Based on its<br />pharmacodynamic properties, Irbesartan is unlikely to affect this ability. When driving vehicles or<br />operating machines, it should be taken into account that dizziness or weariness may occur during<br />treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In placebo-controlled trials in patients with hypertension, the overall incidence of adverse events did<br />not differ between the Irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation due to any<br />clinical or laboratory adverse event was less frequent for Irbesartan-treated patients (3.3%) than for<br />placebo-treated patients (4.5%). The incidence of adverse events was not related to dose (in the<br />recommended dose range), gender, age, race, or duration of treatment.<br />In diabetic hypertensive patients with microalbuminuria and normal renal function, orthostatic<br />dizziness and orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon) but in<br />excess of placebo.<br />The following table presents the adverse drug reactions that were reported in placebo-controlled trials<br />in which 1,965 hypertensive patients received irbesartan. Terms marked with a star (*) refer to the<br />adverse reactions that were additionally reported in &gt; 2% of diabetic hypertensive patients with chronic<br />renal insufficiency and overt proteinuria and in excess of placebo.<br />The frequency of adverse reactions listed below is defined using the following convention:<br />very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge;<br />1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are<br />presented in order of decreasing seriousness.<br />Adverse reactions additionally reported from post&ndash;marketing experience are also listed. These adverse<br />reactions are derived from spontaneous reports.</p><p>&nbsp;</p><p>Blood and lymphatic system disorders<br />Not known: thrombocytopenia<br />Immune system disorders:<br />Not known: hypersensitivity reactions such as angioedema, rash, urticaria<br />Metabolism and nutrition disorders:<br />Not known: hyperkalaemia<br />Nervous system disorders:<br />Common: dizziness, orthostatic dizziness*<br />Not known: vertigo, headache<br />Ear and labyrinth disorder:<br />Not known: tinnitus<br />Cardiac disorders:<br />Uncommon: tachycardia<br />Vascular disorders:<br />Common: orthostatic hypotension*<br />Uncommon: flushing<br />Respiratory, thoracic and meditational disorders:<br />Uncommon: cough<br />Gastrointestinal disorders:<br />Common: nausea/vomiting<br />Uncommon: diarrhoea, dyspepsia/heartburn<br />Not known: dysgeusia<br />Hepatobiliary disorders:<br />Uncommon: jaundice<br />Not known: hepatitis, abnormal liver function</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders:<br />Not known: leukocytoclastic vasculitis<br />Musculoskeletal and connective tissue disorders:<br />Common: musculoskeletal pain*<br />Not known: arthralgia, myalgia (in some cases associated with increased plasma creatine kinase<br />levels), muscle cramps<br />Renal and urinary disorders:<br />Not known: impaired renal function including cases of renal failure in patients at risk (see section<br />4.4)<br />Reproductive system and breast disorders:<br />Uncommon: sexual dysfunction<br />General disorders and administration site conditions:<br />Common: fatigue<br />Uncommon: chest pain<br />Investigations:<br />Very common: Hyperkalaemia* occurred more often in diabetic patients treated with Irbesartan than<br />with placebo. In diabetic hypertensive patients with microalbuminuria and normal<br />renal function, hyperkalaemia (&ge; 5.5 mEq/L) occurred in 29.4% of the patients in the<br />Irbesartan 300 mg group and 22% of the patients in the placebo group. In diabetic<br />hypertensive patients with chronic renal insufficiency and overt proteinuria,<br />hyperkalaemia (&ge; 5.5 mEq/L) occurred in 46.3% of the patients in the Irbesartan<br />group and 26.3% of the patients in the placebo group.<br />Common: significant increases in plasma creatine kinase were commonly observed (1.7%) in<br />Irbesartan treated subjects. None of these increases were associated with identifiable<br />clinical musculoskeletal events.<br />In 1.7% of hypertensive patients with advanced diabetic renal disease treated with<br />Irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been<br />observed&nbsp;</p><p>Paediatric population:<br />In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following<br />adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%),<br />dizziness (1.9%), cough (0.9%). In the 26-week open-label period of this trial the most frequent<br />laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of<br />child recipients.<br />To report any side effect(s):<br /> Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br /> Other GCC States:<br /> Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience in adults exposed to doses of up to 900 mg/day for 8 weeks revealed no toxicity. The most<br />likely manifestations of overdose are expected to be hypotension and tachycardia; bradycardia might<br />also occur from overdose. No specific information is available on the treatment of overdose with<br />Irbesartan. The patient should be closely monitored, and the treatment should be symptomatic and<br />supportive. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal<br />may be useful in the treatment of overdose. Irbesartan is not removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-II antagonists, plain.<br />ATC code: C09C A04.<br />Mechanism of action: Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1)<br />antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless<br />of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II<br />(AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in<br />plasma aldosterone concentration. Serum potassium levels are not significantly affected by Irbesartan<br />alone at the recommended doses. Irbesartan does not inhibit ACE (kininase-II), an enzyme which<br />generates angiotensin-II and also degrades bradykinin into inactive metabolites. Irbesartan does not<br />require metabolic activation for its activity.<br />Clinical efficacy:<br />Hypertension<br />Irbesartan lowers blood pressure with minimal change in heart rate. The decrease in blood pressure is<br />dose-related for once a day doses with a tendency towards plateau at doses above 300 mg. Doses of<br />150-300 mg once daily lower supine or seated blood pressures at trough (i.e. 24 hours after dosing) by<br />an average of 8-13/5-8 mm Hg (systolic/diastolic) greater than those associated with placebo.<br />Peak reduction of blood pressure is achieved within 3-6 hours after administration and the blood<br />pressure lowering effect is maintained for at least 24 hours. At 24 hours the reduction of blood pressure<br />was 60-70% of the corresponding peak diastolic and systolic responses at the recommended doses.<br />Once daily dosing with 150 mg produced trough and mean 24 hour responses similar to twice daily<br />dosing on the same total dose.<br />The blood pressure lowering effect of Irbesartan is evident within 1-2 weeks, with the maximal effect<br />occurring by 4-6 weeks after start of therapy. The antihypertensive effects are maintained during long<br />term therapy. After withdrawal of therapy, blood pressure gradually returns toward baseline. Rebound<br />hypertension has not been observed.</p><p>The blood pressure lowering effects of Irbesartan and thiazide-type diuretics are additive. In patients<br />not adequately controlled by Irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5<br />mg) to Irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of<br />7-10/3-6 mm Hg (systolic/diastolic).<br />The efficacy of Irbesartan is not influenced by age or gender. As is the case with other medicinal<br />products that affect the renin-angiotensin system, black hypertensive patients have notably less<br />response to Irbesartan monotherapy. When Irbesartan is administered concomitantly with a low dose of<br />hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches<br />that of white patients.<br />There is no clinically important effect on serum uric acid or urinary uric acid secretion.<br />Paediatric population<br />Reduction of blood pressure with 0.5 mg/kg (low), 1.5 mg/kg (medium) and 4.5 mg/kg (high) target<br />titrated doses of Irbesartan was evaluated in 318 hypertensive or at risk (diabetic, family history of<br />hypertension) children and adolescents aged 6 to 16 years over a three week period. At the end of the<br />three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic<br />blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high<br />dose). No significant difference was apparent between these doses. Adjusted mean change of trough<br />seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium<br />dose), 5.6 mmHg (high dose). Over a subsequent two week period where patients were re-randomized<br />to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in<br />SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of<br />Irbesartan (see section 4.2).<br />Hypertensionandtype2diabeteswithrenaldisease<br />The &ldquo;Irbesartan Diabetic Nephropathy Trial (IDNT)&rdquo; shows that Irbesartan decreases the progression of<br />renal disease in patients with chronic renal insufficiency and overt proteinuria. IDNT was a double<br />blind, controlled, morbidity and mortality trial comparing Irbesartan, amlodipine and placebo. In 1,715<br />hypertensive patients with type 2 diabetes, proteinuria &ge; 900 mg/day and serum creatinine ranging from<br />1.0-3.0 mg/dl, the long-term effects (mean 2.6 years) of Irbesartan on the progression of renal disease<br />and all-cause mortality were examined. Patients were titrated from 75 mg to a maintenance dose of 300&nbsp;mg Irbesartan, from 2.5 mg to 10 mg amlodipine, or placebo as tolerated. Patients in all treatment<br />groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha<br />blockers) to reach a predefined blood pressure goal of &le; 135/85 mmHg or a 10 mmHg reduction in<br />systolic pressure if baseline was &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group<br />reached this target blood pressure whereas this figure was 76% and 78% in the Irbesartan and<br />amlodipine groups respectively. Irbesartan significantly reduced the relative risk in the primary<br />combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or all-cause<br />mortality. Approximately 33% of patients in the Irbesartan group reached the primary renal composite<br />endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction<br />versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)]. When<br />the individual components of the primary endpoint were analysed, no effect in all cause mortality was<br />observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of<br />serum creatinine were observed.<br />Subgroups consisting of gender, race, age, duration of diabetes, baseline blood pressure, serum<br />creatinine, and albumin excretion rate were assessed for treatment effect. In the female and black<br />subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit<br />was not evident, although the confidence intervals do not exclude it. As for the secondary endpoint of<br />fatal and non-fatal cardiovascular events, there was no difference among the three groups in the overall<br />population, although an increased incidence of non-fatal MI was seen for women and a decreased<br />incidence of non-fatal MI was seen in males in the Irbesartan group versus the placebo-based regimen.<br />An increased incidence of non-fatal MI and stroke was seen in females in the irbesartan-based regimen<br />versus the amlodipine-based regimen, while hospitalization due to heart failure was reduced in the<br />overall population. However, no proper explanation for these findings in women has been identified.<br />The study of the &ldquo;Effects of Irbesartan on Microalbuminuria in Hypertensive Patients with type 2<br />Diabetes Mellitus (IRMA 2)&rdquo; shows that Irbesartan 300 mg delays progression to overt proteinuria in<br />patients with microalbuminuria. IRMA 2 was a placebo-controlled double blind morbidity study in 590<br />patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum<br />creatinine &le; 1.5 mg/dl in males and &lt; 1.1 mg/dl in females). The study examined the long-term effects<br />(2 years) of Irbesartan on the progression to clinical (overt) proteinuria (urinary albumin excretion rate&nbsp;(UAER) &gt; 300 mg/day, and an increase in UAER of at least 30% from baseline). The predefined blood<br />pressure goal was &le; 135/85 mmHg. Additional antihypertensive agents (excluding ACE inhibitors,<br />angiotensin II receptor antagonists and dihydropyridine calcium blockers) were added as needed to help<br />achieve the blood pressure goal. While similar blood pressure was achieved in all treatment groups,<br />fewer subjects in the Irbesartan 300 mg group (5.2%) than in the placebo (14.9%) or in the Irbesartan<br />150 mg group (9.7%) reached the endpoint of overt proteinuria, demonstrating a 70% relative risk<br />reduction versus placebo (p = 0.0004) for the higher dose. An accompanying improvement in the<br />glomerular filtration rate (GFR) was not observed during the first three months of treatment. The<br />slowing in the progression to clinical proteinuria was evident as early as three months and continued<br />over the 2 year period. Regression to normoalbuminuria (&lt; 30 mg/day) was more frequent in the<br />Irbesartan 300 mg group (34%) than in the placebo group (21%).<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in<br />combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs<br />Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an<br />angiotensin II receptor blocker. ONTARGET was a study conducted in patients with a history of<br />cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of endorgan<br />damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic<br />nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as<br />compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results<br />are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints)<br />was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or<br />an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease,<br />cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse&nbsp;outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group<br />than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia,<br />hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the<br />placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration, Irbesartan is well absorbed: studies of absolute bioavailability gave values of<br />approximately 60-80%. Concomitant food intake does not significantly influence the bioavailability of<br />irbesartan. Plasma protein binding is approximately 96%, with negligible binding to cellular blood<br />components. The volume of distribution is 53 - 93 litres. Following oral or intravenous administration<br />of 14C irbesartan, 80-85% of the circulating plasma radioactivity is attributable to unchanged irbesartan.<br />Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation. The major circulating<br />metabolite is Irbesartan glucuronide (approximately 6%). In vitro studies indicate that Irbesartan is<br />primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible<br />effect.<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg.<br />A less than proportional increase in oral absorption at doses beyond 600 mg (twice the maximal<br />recommended dose) was observed; the mechanism for this is unknown. Peak plasma concentrations are<br />attained at 1.5 - 2 hours after oral administration. The total body and renal clearance are 157 - 176 and<br />3 - 3.5 ml/min, respectively. The terminal elimination half-life of Irbesartan is 11 - 15 hours. Steadystate<br />plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen.<br />Limited accumulation of Irbesartan (&lt; 20%) is observed in plasma upon repeated once-daily dosing. In<br />a study, somewhat higher plasma concentrations of Irbesartan were observed in female hypertensive<br />patients. However, there was no difference in the half-life and accumulation of irbesartan. No dosage<br />adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater<br />in oldersubjects (&ge; 65 years) than those of young subjects (18 - 40 years). However the terminal halflife<br />was not significantly altered. No dosage adjustment is necessary in older people.<br />Irbesartan and its metabolites are eliminated by both biliary and renal pathways. After either oral or IV<br />administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the<br />remainder in the faeces. Less than 2% of the dose is excreted in the urine as unchanged irbesartan.</p><p>Paediatric population<br />The pharmacokinetics of Irbesartan were evaluated in 23 hypertensive children after the administration<br />of single and multiple daily doses of Irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for<br />four weeks. Of those 23 children, 21 were evaluable for comparison of pharmacokinetics with adults<br />(twelve children over 12 years, nine children between 6 and 12 years). Results showed that Cmax, AUC<br />and clearance rates were comparable to those observed in adult patients receiving 150 mg Irbesartan<br />daily. A limited accumulation of Irbesartan (18%) in plasma was observed upon repeated once daily<br />dosing.<br />Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the<br />pharmacokinetic parameters of Irbesartan are not significantly altered. Irbesartan is not removed by<br />haemodialysis.<br />Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of<br />Irbesartan are not significantly altered.<br />Studies have not been performed in patients with severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of abnormal systemic or target organ toxicity at clinically relevant doses. In nonclinical<br />safety studies, high doses of Irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100 mg/kg/day in<br />macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit). At<br />very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidney (such as interstitial nephritis,<br />tubular distension, basophilic tubules, increased plasma concentrations of urea and creatinine) were<br />induced by Irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects<br />of the medicinal product which led to decreased renal perfusion. Furthermore, Irbesartan induced<br />hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in macaques at &ge; 10<br />mg/kg/day). All of these changes were considered to be caused by the pharmacological action of<br />irbesartan. For therapeutic doses of Irbesartan in humans, the hyperplasia/ hypertrophy of the renal<br />juxtaglomerular cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</p><p>Fertility and reproductive performance were not affected in studies of male and female rats even at oral<br />doses of Irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at<br />the highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were<br />observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in<br />animals<br />Indicate that the radiolabeled Irbesartan is detected in rat and rabbit fetuses. Irbesartan is excreted in the<br />milk of lactating rats.<br />Animal studies with Irbesartan showed transient toxic effects (increased renal pelvic cavitation,<br />hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits,<br />abortion or early resorption were noted at doses causing significant maternal toxicity, including<br />mortality. No<br />teratogenic effects were observed in the rat or rabbit.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p> Colloidal Silicon Dioxide-Aerosil 200<br /> Croscarmellose Sodium<br /> Lactose Anhydrus DC Gr.<br /> Magnesium Stearate<br /> Maize Starch<br /> Microcrystalline Cellulose PH102<br /> Poloxamer 188<br /> Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary Packing: Aluminium PVC/PVDC blisters.<br />Secondary Packing: Carton with PIL</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>